Rapaflo (Watson) Laboratories-Open for enrollment

A prospective, multi center evaluation of the urodynamic benefits of Silodosin in men with bladder outlet obstruction associated with benign prostatic hyperplasia.

Inclusion Criteria:

  • Age > 45 years
  • Has a diagnosis of benign prostatic hyperplasia(BPH)
  • Has experienced lower urinary tract symptoms associated with BPH for at least 3 months prior to screening.
  • Has a bladder outlet obstruction index (BOOI) > 40 from urodynamic assessment